Medicare Enrolled
Dr. Ramesh Moolani, M.D.
Internal Medicine · Chula Vista, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Moolani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Moolani?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Moolani
Dr. Ramesh Moolani is an internal medicine specialist in Chula Vista, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Moolani performed 16,803 Medicare services across 765 unique beneficiaries.
Between the years covered by Open Payments, Dr. Moolani received a total of $23,230 from 90 pharmaceutical and/or device companies across 972 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Moolani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 1% volume in CA
$23,230 industry payments
Medicare Practice Summary
Medicare Utilization ↗16,803
Medicare services
Top 1% in CA for internal medicine
765
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~884 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
6,450 | $0 | $0 |
| Denosumab injection (Prolia/Xgeva) | 5,040 | $19 | $43 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,412 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 811 | $1 | $2 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
755 | $8 | $10 |
| Pegfilgrastim-jmdb injection An injection of pegfilgrastim-jmdb, a biosimilar medication. The dose specified is 0.5 mg. |
468 | $101 | $360 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
260 | $116 | $220 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
218 | $107 | $190 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
211 | $12 | $40 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
198 | $6 | $13 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
172 | $24 | $55 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
142 | $25 | $45 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
129 | $8 | $30 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
125 | $13 | $40 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
120 | $57 | $110 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
79 | $17 | $30 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
76 | $98 | $190 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
54 | $54 | $105 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
31 | $143 | $250 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
30 | $152 | $220 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
22 | $127 | $225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.9% high complexity
88.6% medium
7.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,230
Total received (2018-2024)
Avg $3,319/year across 7 years
Top 5% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
90
Companies
972
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$19,450 (83.7%)
Other
Charitable contributions, space rental, and other categories
$2,993 (12.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$787 (3.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,304
2023
$4,971
2022
$3,858
2021
$4,319
2020
$1,633
2019
$2,160
2018
$985
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,281
Merck Sharp & Dohme LLC
$314
AstraZeneca Pharmaceuticals LP
$300
Janssen Biotech, Inc.
$280
Celgene Corporation
$239
PFIZER INC.
$226
SOBI, INC
$168
Daiichi Sankyo Inc.
$164
ABBVIE INC.
$157
E.R. Squibb & Sons, L.L.C.
$153
Incyte Corporation
$152
PUMA BIOTECHNOLOGY, INC.
$127
Alexion Pharmaceuticals, Inc.
$122
Takeda Pharmaceuticals U.S.A., Inc.
$118
Amgen Inc.
$116
Rigel Pharmaceuticals, Inc.
$115
Regeneron Healthcare Solutions, Inc.
$111
Eisai Inc.
$110
Astellas Pharma US Inc
$98
Bayer Healthcare Pharmaceuticals Inc.
$89
ARRAY BIOPHARMA INC
$78
Exelixis Inc.
$68
Pharmacosmos Therapeutics Inc.
$64
Kite Pharma, Inc.
$61
Lilly USA, LLC
$58
Gilead Sciences, Inc.
$51
BeiGene USA, Inc.
$48
EMD Serono, Inc.
$47
GlaxoSmithKline, LLC.
$33
Karyopharm Therapeutics Inc.
$32
Stemline Therapeutics Inc.
$31
RECORDATI_RARE_DISEASES_INC.
$29
TerSera Therapeutics LLC
$28
Acrotech Biopharma Inc.
$26
Genmab U.S., Inc.
$25
Mirati Therapeutics, Inc.
$24
Coherus Biosciences Inc.
$24
Ipsen Biopharmaceuticals, Inc
$24
SERVIER PHARMACEUTICALS LLC
$22
JAZZ PHARMACEUTICALS INC.
$22
ImmunoGen, Inc.
$21
Octapharma USA, Inc.
$16
Alnylam Pharmaceuticals Inc.
$16
Amneal Pharmaceuticals LLC
$15
Top 3 companies account for 35.7% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$4,365
AstraZeneca Pharmaceuticals LP
$1,525
Janssen Biotech, Inc.
$1,123
PFIZER INC.
$1,071
Takeda Pharmaceuticals U.S.A., Inc.
$967
Merck Sharp & Dohme LLC
$831
E.R. Squibb & Sons, L.L.C.
$796
Amgen Inc.
$734
Pharmacyclics LLC, An AbbVie Company
$687
Celgene Corporation
$669
Seagen Inc.
$599
Astellas Pharma US Inc
$528
Incyte Corporation
$519
Merck Sharp & Dohme Corporation
$499
Daiichi Sankyo Inc.
$405
Eisai Inc.
$324
BeiGene USA, Inc.
$301
Epizyme, Inc.,
$299
Lilly USA, LLC
$292
Alexion Pharmaceuticals, Inc.
$291
Kite Pharma, Inc.
$289
Rigel Pharmaceuticals, Inc.
$288
Regeneron Healthcare Solutions, Inc.
$283
Exelixis Inc.
$282
PUMA BIOTECHNOLOGY, INC.
$268
Bayer Healthcare Pharmaceuticals Inc.
$253
SOBI, INC
$252
NOVARTIS PHARMACEUTICALS CORPORATION
$250
Gilead Sciences, Inc.
$247
Bayer HealthCare Pharmaceuticals Inc.
$208
ABBVIE INC.
$199
Puma Biotechnology, Inc.
$193
Genentech USA, Inc.
$190
Karyopharm Therapeutics Inc.
$168
Dova Pharmaceuticals
$163
Blueprint Medicines Corporation
$154
EISAI INC.
$152
Ipsen Biopharmaceuticals, Inc
$148
ARRAY BIOPHARMA INC
$136
Mirati Therapeutics, Inc.
$119
Sobi, Inc
$113
Verastem, Inc.
$97
GlaxoSmithKline, LLC.
$93
EMD Serono, Inc.
$91
Boehringer Ingelheim Pharmaceuticals, Inc.
$84
Pharmacosmos Therapeutics Inc.
$84
Secura Bio, Inc.
$82
Pharmacyclics LLC, an AbbVie Company
$81
Dendreon Pharmaceuticals LLC
$75
Taiho Oncology, Inc.
$72
Coherus Biosciences Inc.
$72
Seattle Genetics, Inc.
$71
Acrotech Biopharma Inc.
$64
EUSA Pharma (US) LLC
$57
TerSera Therapeutics LLC
$52
Lexicon Pharmaceuticals, Inc.
$48
JAZZ PHARMACEUTICALS INC.
$45
AbbVie, Inc.
$44
Myriad Genetic Laboratories, Inc.
$44
Foundation Medicine, Inc.
$43
SERVIER PHARMACEUTICALS LLC
$42
Amneal Pharmaceuticals LLC
$40
Heron Therapeutics, Inc.
$40
Janssen Pharmaceuticals, Inc
$39
CSL Behring
$33
Stemline Therapeutics Inc.
$31
Janssen Scientific Affairs, LLC
$29
Teva Pharmaceuticals USA, Inc.
$29
ADC Therapeutics America, Inc.
$29
RECORDATI_RARE_DISEASES_INC.
$29
Myovant Sciences Inc.
$29
Deciphera Pharmaceuticals Inc.
$27
Genmab U.S., Inc.
$25
Sun Pharmaceutical Industries Inc.
$25
West Therapeutics Development, LLC
$24
Servier Pharmaceuticals LLC
$23
Acrotech Biopharma LLC
$23
AMAG Pharmaceuticals, Inc.
$23
Shire North American Group Inc
$22
GENZYME CORPORATION
$21
ImmunoGen, Inc.
$21
Clovis Oncology, Inc.
$19
Spectrum Pharmaceuticals Inc.
$18
Apellis Pharmaceuticals, Inc.
$17
SANOFI-AVENTIS U.S. LLC
$17
Octapharma USA, Inc.
$16
Alnylam Pharmaceuticals Inc.
$16
AVEO Pharmaceuticals, Inc.
$16
Sirtex Medical Inc
$15
Array BioPharma Inc.
$14
Top 3 companies account for 30.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALUNBRIG · AMVUTTRA · AVASTIN · AYVAKIT · Abraxane · Afstyla · Alecensa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · BYNFEZIA PEN · Balversa · Bavencio · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · CYRAMZA · Cabometyx · Cinvanti · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIQUIS · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Empaveli · Enhertu · Epkinly · Erleada · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAVRETO · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lazanda · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Padcev · Pomalyst · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Rezlidhia · Rubraca · SANDOSTATIN LAR · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SYLVANT · Stivarga · Sustol · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEVIMBRA · TIBSOVO · TUKYSA · Tavalisse · Tazverik · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VELCADE · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YERVOY · Yescarta · ZEJULA · ZEPZELCA · Zoladex
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 5% for internal medicine in CA.
Geographic Context
Internal medicine physicians within 10 mi
1,387
Per 100K population
42.3
County median income
$102,285
Nearest hospital
SHARP CHULA VISTA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Moolani is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with low-engagement industry engagement in the top 5% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Moolani experienced with anti-nausea injection (fosaprepitant)?
Based on Medicare claims data, Dr. Moolani performed 6,450 anti-nausea injection (fosaprepitant) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Moolani receive payments from pharmaceutical companies?
Yes. Dr. Moolani received a total of $23,230 from 90 companies across 972 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Moolani's costs compare to other internal medicine physicians in Chula Vista?
Dr. Moolani's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Moolani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Chula Vista
Browse internal medicine physicians in Chula Vista ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology